title: [Treatment results of salvage radiotherapy for biochemical recurrence after radical prostatectomy].
abstract: OBJECTIVE
  In this retrospective study we reported the results of salvage external beam radiotherapy for patients with biochemical recurrence after radical prostatectomy.
  
  
  METHODS
  A total of 28 patients with biochemical recurrence after radical prostatectomy underwent salvage radiotherapy with (n=16) or without (n=12) hormonal therapy. Median radiation dose was 60 Gy. Biochemical recurrence after radiotherapy was defined as a single prostate-specific antigen (PSA) of at least 0.1 ng/ml. Potential risk factors were evaluated for significant associations with biochemical recurrence.
  
  
  RESULTS
  The median follow-up period after salvage radiotherapy was 42 months. The actuarial biochemical recurrence free survival rate at 3 and 5 years was 81% and 74%, respectively. Addition of hormonal therapy to salvage radiotherapy did not alter biochemical recurrence rate (P = 0.56). Univariate analysis revealed that Gleason score of 8 to 10 (P = 0.026) and PSA before salvage therapy greater than 0.24 ng/ml (P = 0.0016) were significant risk factors for biochemical recurrence. On multivariate analysis, PSA before salvage therapy greater than 0.24 ng/ml (P = 0.017) maintained statistical significance. Of 28 patients 3 (11%) experienced late grade 3 toxicity of hematuria.
  
  
  CONCLUSIONS
  Our data suggest that early use of salvage radiotherapy is beneficial for patients with biochemical recurrence after radical prostatectomy.
authors.affiliation: Department of Urology, Ikeda Municipal Hospital.
authors.forename: Koji
authors.initials: K
authors.lastname: Hatano
authors.forename: Toshiro
authors.initials: T
authors.lastname: Kinouchi
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Kinoshita
authors.forename: Masao
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Inoue
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Takada
authors.forename: Tsuneo
authors.initials: T
authors.lastname: Hara
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000532:radiotherapy*; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy* / Q000601:surgery*; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D012307:Risk Factors; D016879:Salvage Therapy; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen